Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications
NEW YORK,
Both abstracts are scheduled for presentation in the Experimental and Molecular Therapeutics category under the session titled Radiopharmaceutical Platforms for Theranostic Precision Oncology on
In accordance with AACR embargo policies, details of the abstracts, including titles and full text, will become publicly available on
Presentation Details
Presentation #1:
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time:
Location: Poster Section 16
Poster Board Number: 18
Poster Number: 5824
Presentation #2:
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time:
Location: Poster Section 16
Poster Board Number: 21
Poster Number: 5827
Actinium's Platform Strategy for Long-Term Value Creation
The AACR 2026 data will highlight Actinium's differentiated biology-driven approach to targeted radiotherapy development including:
- Targeting resistance-associated biology rather than tumor surface expression alone
- Leveraging the high-linear energy transfer (LET) of Ac-225 to deliver potent, tumor-specific cytotoxicity
- Building a radiotherapy franchise comprised of multiple pan-tumor assets
Sandesh Seth, Chairman and CEO of
About
Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. ATNM-400, Actinium's lead product candidate, is a novel, first-in-class, and multi-indication Actinium-225 (Ac-225) in development for prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. The antigen specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), contributes directly to disease progression, poorer survival outcomes, and continues to be expressed at a high level even after androgen receptor inhibitor (ARPI) and Pluvicto® treatment. ATNM-400 is supported by preclinical data demonstrating tumor-specific uptake, higher efficacy than androgen receptor inhibitor enzalutamide (Xtandi®) and 177Lu-PSMA-617 radiotherapy, the active agent in Pluvicto®, durable tumor control and potent efficacy in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617. In addition, ATNM-400 has demonstrated synergy with enzalutamide. In NSCLC, ATNM-400 showed superior efficacy to EGFR targeting therapies including osimertinib (TARGRISSO®, AstraZeneca), Dato-DXd (DATROWAY®, AstraZeneca/Daiichi Sankyo) and amivantamab (RYBREVANT®, J&J) with synergistic activity in combination with osimertinib. In breast cancer, ATNM-400 works as monotherapy in triple-negative breast cancer, hormone-positive breast cancer and also in HER2-therapy trastuzumab (HERCEPTIN® Roche) resistant breast cancer and endocrine therapy-resistant breast cancer models. The data generated to date with ATNM-400 supports its potential across treatment settings to be used either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the
For more information, please visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "
Investors:
investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-two-abstracts-at-the-2026-aacr-annual-meeting-302689485.html
SOURCE
